Asset Details
Do you wish to reserve the book?
Introduction of IgM testing for the diagnosis of acute Lyme borreliosis: a study of the benefits, limitations and costs
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Introduction of IgM testing for the diagnosis of acute Lyme borreliosis: a study of the benefits, limitations and costs
Do you wish to request the book?
Introduction of IgM testing for the diagnosis of acute Lyme borreliosis: a study of the benefits, limitations and costs
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Introduction of IgM testing for the diagnosis of acute Lyme borreliosis: a study of the benefits, limitations and costs
2022
Overview
Testing for IgM antibodies to
Borrelia burgdorferi
in Scottish patients with suspected Lyme borreliosis was introduced in 2018 to supplement the IgG testing already in situ. Results from 2018 to 2020 were assessed alongside available clinical data to evaluate the utility of IgM testing in serum. An estimated false positive rate of 25.5% was observed with IgM immunoblot vs 80.1% for IgM chemiluminescent immunoassay (CLIA). IgM testing can aid earlier diagnoses if used within a selective two-tier testing protocol: only patients with acute onset of symptoms should be tested for IgM CLIA but confirmation by immunoblot and consideration of clinical picture is necessary.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
